WuXi Biologics (Cayman) Inc.
WXIBF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | $97 | $65 | $43 | $118 |
| - Cash | $8 | $8 | $9 | $10 |
| + Debt | $5 | $5 | $5 | $5 |
| Enterprise Value | $93 | $61 | $39 | $113 |
| Revenue | $10 | $10 | $9 | $9 |
| % Growth | -1.5% | 17.8% | 0.4% | – |
| Gross Profit | $4 | $4 | $3 | $3 |
| % Margin | 42.7% | 42.6% | 39.1% | 38.2% |
| EBITDA | $3 | $4 | $2 | $2 |
| % Margin | 34.7% | 39.2% | 28.8% | 24.9% |
| Net Income | $2 | $2 | $1 | $1 |
| % Margin | 23.5% | 18.4% | 17.5% | 13.3% |
| EPS Diluted | 0.55 | 0.43 | 0.35 | 0.26 |
| % Growth | 27.9% | 22.9% | 34.6% | – |
| Operating Cash Flow | $2 | $4 | $1 | $2 |
| Capital Expenditures | -$2 | -$2 | -$2 | -$2 |
| Free Cash Flow | -$0 | $2 | -$1 | $0 |